Peter Rost (doctor)
Peter Rost, M.D. is a former drug marketing executive and is most well known for taking public stances critical of the pharmaceutical industry as an "insider" and whistleblower. He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005. Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant.
Rost worked at medical advertising agencies prior to starting to work for pharmaceutical companies.
Rost started working at Wyeth in approximately 1992; seven years after joining Wyeth, he was promoted to head Wyeth-Lederle Nordiska, Wyeth's Scandinavian subsidiary, and Rost has said that he doubled sales during his tenure. He became concerned about Wyeth's accounting practices and filed a lawsuit against them over that, and a second lawsuit over what he considered to be a retaliatory job change.
Rost left Wyeth for Pharmacia in June 2001 and took a role leading its endocrinology division, and said that he soon began to be concerned from a business perspective about sales of Genotropin, Pfizer's human growth hormone drug, which had plateaued; Pharmacia's decision to pour money into off-label marketing to adults was not paying off, due to the low doses that adults took. In the next year, Rost became aware that the strategy was not only unwise, but was probably illegal, and began raising objections internally to try to get the company to change course. In July 2002 merger discussions with Pfizer were announced, and Rost and other executives briefed the Pfizer acquisition team on the issues with Genotropin as the merger talks progressed. However, when news broke in January 2013 of Rost's lawsuits against Wyeth (see below), things turned sour; Rost reported getting an email from his future Pfizer boss saying "There will not be a fit with the marketing organization" for him. The merger with Pfizer was completed in April 2003. Rost was offered a severance package, as other Pharmacia executives were, but Pfizer and Rost failed to come to agreement, and Pfizer did not fire him, as they were aware of the suit he filed against them related to Genotropin marketing (see below). His staff of 60 was slowly reassigned and by the end of summer 2003, he was left with his administrative assistant, who was re-assigned in the summer of 2004, and his office was moved to an out of the way location.
In August 2004, Rost posted a glowing review of Marcia Angell's book, The Truth About the Drug Companies: How They Deceive Us and What to Do About It on amazon.com. The review was noticed by a reporter at USA Today, which interviewed him for an article on the drug industry. The public spotlight from the USA Today article "changed Rost’s life" and launched Rost's new career as an insider critical of the drug industry.
In September 2004 Rost testified at a Congressional hearing over the reimportation of drugs, in which he stated that "Holding up a vote on importation, stopping good importation bills has a high, high cost not just in money, but in American lives. Every day we delay, Americans die because they cannot afford life-saving drugs." Pfizer responded by sending a letter to Congress that said, "Dr. Rost has no qualifications to speak on importation, no responsibilities in this area at Pfizer, no knowledge of the information and analysis Pfizer has provided to the government on this issue, and no substantive grasp of how importation may impact the safety of this nation's drug supply." Rost followed up that testimony with an opinion piece published by the New York Times. In mid 2005 Rost appeared on a 60 Minutes segment about drug pricing.
In late 2005 Rost's lawsuit against Pfizer under the False Claims Act was unsealed (see below) and in December 2005, Pfizer fired him. At Pfizer, Rost had made $600,000 per year for "by his own account, doing essentially no work".
Rost started blogging at The Huffington Post, but was banned in June 2006, after he got into a tiff with a heckler on his blog, who turned out to be on the Post's technical staff. Arianna Huffington said, "It seemed like his blog was becoming about personal grudges. That would have been no problem if the posts were interesting."
In September 2006, Rost's book, The Whistleblower, Confessions of a Healthcare Hitman was published, which described Rost’s tenure at Pharmacia and Pfizer and his efforts to deal with the marketing of Genotropin. In 2007, he published Killer Drug, a novel about a fictional drug company that develops a biological weapon for the military.
In August 2007 Rost started to write a daily blog for BrandweekNRX and a column for Realtid, a Swedish online business newspaper. Later in 2007 Rost announced his new business venture, as a Pharmaceutical Marketing Expert Witness.
In January 2003, the New York Times published an article describing a whistleblowing lawsuit Rost had filed against Wyeth, claiming that Wyeth had practiced tax and compensation fraud worldwide, and describing Rost's separate lawsuit against Wyeth for removing him from heading a staff of 125 Wyeth-Lederle Nordiska to heading a group of eight people in New Jersey, which Rost described as a retaliatory demotion and Wyeth described as a promotion. Later in 2003, Wyeth settled the whistleblowing lawsuit for an undisclosed amount.
In June 2003 Rost filed a case under the False Claims Act (FCA) against Pfizer, claiming that Pharmacia defrauded the government by causing false claims to be filed, due to Pharmacia's illegal off-label marketing of Genotropin. The case was unsealed in November 2005, and the Department of Justice declined to intervene, leaving Rost to litigate on his own. After Pfizer fired him in December 2005, Rost filed a wrongful termination lawsuit, while Pfizer claimed that they had planned to eliminate his position due to redundancies from the merger in 2003, but that they had kept him because they were aware of the FCA suit he had filed. Pfizer also claimed that they had informed the FDA of Pharmacia's marketing and kickback practices two weeks prior to Rost filing his FCA lawsuit and that they could not do so earlier due to securities laws related to the Pharmacia merger; they also claimed that government's decision not to intervene supported their contention that the lawsuit was baseless.
Rost's FCA lawsuit was dismissed in September 2006 for failing to show that Pharmacia's marketing and kickbacks generated fraudulent claims to be submitted to the US Government; Rost appealed.
On April 2, 2007, Pfizer and the Department of Justice, which had been conducting its own investigations focused on kickbacks and illegal off-label marketing (not fraud), announced that two Pharmacia subsidiaries had pled guilty and agreed to pay at total of $34.7 million in civil and criminal penalties for kickbacks and illegally promoting its human growth hormone drug, Genotropin. One subsidiary had offered to overpay a subsidiary of a pharmacy benefit manager, Express Scripts, by $12.3 million to induce it recommend Genotropin over other forms of HGH; the other marketed Genotropin off-label for uses in antiaging, cosmetics, and athletic performance. The DOJ press release praised Pfizer for bringing the matters to the DOJ's attention shortly after the acquisition of Pharmacia.
In November 2007 Rost won his appeal of his FCA case, and the case was sent back to district court, where in September 2010 the judge again dismissed his claims as not proving fraud against the federal government. Rost appealed again, but withdrew his appeal in August 2013 when Pfizer, the Department of Justice, and Rost settled on undisclosed terms.
- Jim Edwards for BrandWeek. March 20, 2006. Bad Medicine. BrandWeek. Original link broken, Created link from internet archive on August 9, 2014. Archive date March 28, 2006.
- David Cay Johnson and Melody Petersen for the New York Times. January 17, 2003 Whistle-Blower Accuses Wyeth Of Tax Dodges
- Alex Berensen for the New York Times. December 2, 2005 Pfizer Fires a Vice President Who Criticized the Company's Sales Practices
- Peter Rost, customer review at Amazon.com. August 25, 2004 Fantastic Reading
- By Rita Rubin for USA Today. September 13, 2004 Prescription for reform?
- Jake Whitney for Guernica Magazine. June 11, 2008 Healthscare: Jake Whitney interviews Peter Rost
- Robert Pear for the New York Times. September 24, 2004 Insider Challenges Drug Industry on Imports
- Peter Rost. Opinion piece in the New York Times. October 30, 2004 Medicines Without Borders
- Alex Berenson for the New York Times. June 8, 2005 At Pfizer, the Isolation Increases for a Whistle-Blower
- Maria Aspan for the New York Times. June 26, 2006 A Blogger Is Bounced From the Huffington Post
- BrandweekNRX August 2007
- Rost's Litigation Consultant website
- Peter Rost's personal blog
- David Rooney for Hollywood Reporter. January 18, 2013 Fire in the Blood: Sundance Review
- Kirsty Barnes for In-Pharma Technogist. January 6, 2006 http://www.in-pharmatechnologist.com/Regulatory-Safety/The-perils-of-whistleblowing The Perils of Whistleblowing]
- Reuters, in the New York Times. December 14, 2005 Whistle-Blower Sues Pfizer
- Daniel Wilson for Law360 August 23, 2013 Pfizer Settles Former Exec's FCA Suit In 1st Circ.
- Associated Press in the Boston Globe. April 3, 2007 Pfizer units will pay fines in kickback case
- Marius Meland for Law360. April 02, 2007 Pfizer Pays $34.7M To Settle Genotropin Charges